Mydecine Innovations acquires NeuroPharm

Mydecine Innovations today announced it entered a definitive share exchange agreement to acquire 100% of NeuroPharm.

Mydecine Innovations will acquire all issued and outstanding shares in the capital of NeuroPharm for $6 million, which will be payable in common shares in the capital of the company.

NeuroPharm is currently developing evidence-based medicine of psychedelic based therapies to address mental health conditions that are frequently experienced by veterans and frontline workers.

Get the full story on our sister site, Drug Discovery & Development. 

Read more
  • 0